Mark Schoeberg sells 10,000 shares of UroGen (URGN) reported in Form 144

Rhea-AI Filing Summary

Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00. The filing also shows 30,000 ordinary shares issued upon vesting of RSUs on 06/08/2023 (no consideration).

Insights

Corporate Governance Analyst

Routine Form 144 sale by an insider; no additional corporate action shown.

The filing lists a reported disposition of 10,000 ordinary shares by Mark Schoeberg with a transaction date of 05/08/2026 and a reported value of 300,048.00. This appears as a standard insider sale filing under resale rules.

Separately, the record shows 30,000 shares issued upon vesting of RSUs on 06/08/2023 described as "no consideration." Timing and broader portfolio context are not provided in the excerpt.

Key Figures

Shares sold: 10,000 shares Reported value: 300,048.00 RSU shares issued: 30,000 shares

3 metrics

Shares sold 10,000 shares Disposition dated 05/08/2026

Reported value 300,048.00 Associated figure listed with the 10,000-share disposition

RSU shares issued 30,000 shares Issued upon vesting of RSUs on 06/08/2023, no consideration

Key Terms

Form 144, RSUs, No consideration

3 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSUs financial

"Shares issued upon vesting of RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

No consideration financial

"No consideration, shares issued upon vesting of RSUs"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares	Oppenheimer & Co. Inc. 85 Broad St. New York NY 10004	5222	140210.70	48721701	06/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares	06/08/2023	Shares issued upon vesting of RSUs	UroGen Pharma Ltd.			30000	06/08/2023	No consideration, shares issued upon vesting of RSUs

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Schoeberg 9 HA'TA'ASIYA ST RA'ANANA L3 4365007	Ordinary shares	05/08/2026	10000	300048.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does UroGen (URGN) Form 144 report for Mark Schoeberg?

The Form 144 reports a disposition of 10,000 ordinary shares by Mark Schoeberg with a transaction date of 05/08/2026 and an associated figure of 300,048.00 in the filing.

Did the filing show any shares issued to insiders for URGN recently?

Yes; the excerpt shows 30,000 ordinary shares were issued upon vesting of RSUs on 06/08/2023, described as issued with no consideration to the recipient.

Does the Form 144 excerpt state the sale method or buyer for URGN shares?

The excerpt lists the sale quantity and value but does not specify the method of sale or identity of the buyer; the filing text focuses on quantities, dates, and reported value.

Is the 30,000-share RSU issuance linked to the 10,000-share sale in the filing?

The filing shows both items separately: 30,000 shares issued upon RSU vesting on 06/08/2023 and a 10,000-share disposition on 05/08/2026. The excerpt does not state a direct link between them.